Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Clin. transl. oncol. (Print) ; 18(12): 1213-1220, dic. 2016. graf
Article in English | IBECS | ID: ibc-158637

ABSTRACT

Soft-tissue sarcomas are uncommon and heterogeneous tumors of mesenchymal origin. A soft-tissue mass that is increasing in size, greater than 5 cm, or located under deep fascia are criteria for suspicion of sarcoma. Diagnosis, treatment, and management should preferably be performed by a multidisciplinary team in reference centers. MRI and lung CT scan are mandatory for local and distant assessment. A biopsy indicating histological type and grade is needed previous to the treatment. Wide surgical resection with tumor-free tissue margin is the primary treatment for localized disease. Radiotherapy is indicated in large, deep, high-grade tumors, or after marginal resection not likely of being improved with reexcision. Neoadjuvant and adjuvant chemotherapy improve survival in selected cases, usually in high-grade sarcomas of the extremities. In the case of metastatic disease, patients with exclusive lung metastasis could be considered for surgery. First-line treatment with anthracyclines (or in combination with ifosfamide) is the treatment of choice. New drugs have shown activity in second-line therapy and in specific histological subtypes (AU)


No disponible


Subject(s)
Humans , Male , Female , Sarcoma/diagnosis , Sarcoma/therapy , Decision Making/physiology , Image-Guided Biopsy/instrumentation , Image-Guided Biopsy/methods , Dermoid Cyst/complications , Dermoid Cyst/therapy , Societies, Medical/standards , Molecular Biology/methods , Neoplasm Staging/classification , Neoplasm Staging , Neoadjuvant Therapy/methods , Radiotherapy, Adjuvant , Retroperitoneal Neoplasms/classification , Retroperitoneal Neoplasms/complications , Retroperitoneal Neoplasms/therapy
2.
Clin. transl. oncol. (Print) ; 10(4): 235-237, abr. 2008. tab
Article in English | IBECS | ID: ibc-123440

ABSTRACT

Megestrol acetate is a synthetic progestin that has been used since the 1970s for the treatment of advanced cancer and subsequently to treat anorexia, cachexia and weight loss in AIDS patients. It has been shown that high doses or prolonged treatment with this drug may cause Cushing's syndrome, new-onset diabetes and suppression of plasma ACTH and cortisol levels. Megestrol acetate may cause suppression of the pituitary-adrenal axis due to the affinity of this compound for the glucocorticoid receptor. Recognising the glucocorticoid-like activity of megestrol and its effects at the axis level is important for the diagnosis of sub-clinical adrenal insufficiency. We present the case of a 74-year-old woman with infiltrating ductal breast carcinoma refractory to prolonged hormonal treatment with megestrol acetate, presenting with adrenal insufficiency (AU)


No disponible


Subject(s)
Humans , Male , Aged , Adrenal Insufficiency/chemically induced , Adrenal Insufficiency/physiopathology , Antineoplastic Agents, Hormonal/adverse effects , Breast Neoplasms/diagnosis , Breast Neoplasms/drug therapy , Carcinoma, Ductal, Breast/drug therapy , Megestrol Acetate/adverse effects , Pericardial Effusion/complications , Pericardial Effusion/etiology , Pericardial Effusion/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...